Journal article

The rebirth of lithium as the archetypal mood stabilizer

Andre F Carvalho, Marco Solmi, M Ishrat Husain, Michael Berk, Eduard Vieta

Bipolar Disorders | WILEY | Published : 2020

Abstract

The serendipitous discovery of lithium's efficacy for the treatment of manic excitement dates back to initial observations by the Danish psychologist Carl Lange in 1886 who theorised that patients with manic-depressive illness had "cerebral gout" for which he suggested lithium salts because lithium could dissolve urate stones. Modern use was triggered by Cade in Melbourne in 1949, while its efficacy for the management of manic episodes and for the prophylaxis of both manic and bipolar depressive episodes was empirically confirmed by Mogens Schou in Denmark.

University of Melbourne Researchers

Grants

Awarded by NHMRC


Funding Acknowledgements

AFC and MS have nothing to disclose. MIH is a PI for a trial sponsored by COMPASS Pathways Limited for which he receives salary support. MIH receives research support from the Brain and Behavior Research Foundation, CAMH Discovery Seed Fund, PSI Foundation, Stanley Medical Research Institute and University of Toronto. MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Abbot, Astra Zeneca, Janssen and Janssen, Lundbeck and Merck and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier -all unrelated to this work. MB is supported by a NHMRC Senior Principal Research Fellowship 1156072. EV has received research support from or served as consultant, adviser or speaker for AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage pharmaceuticals, Sanofi-Aventis, Shire, Sunovion, Takeda, and reports no financial or other relationship relevant to the subject of this article.